Droxidopa is a synthetic amino acid precursor to norepinephrine, a neurotransmitter and hormone that helps regulate blood pressure [1]. It is prescribed to treat symptomatic orthostatic hypotension (OH), a condition characterized by a sudden drop in blood pressure upon standing, which can cause dizziness, lightheadedness, and fainting [1][2]. Droxidopa works by converting into norepinephrine in the body, thereby increasing blood pressure and reducing OH symptoms [1].
How Does Droxidopa Work to Raise Blood Pressure?
Droxidopa functions as a prodrug, meaning it is converted into its active form within the body [1]. Once administered, droxidopa is metabolized into norepinephrine [1]. Norepinephrine is a catecholamine that acts on alpha-adrenergic receptors in blood vessels, causing them to constrict [1]. This vasoconstriction increases peripheral vascular resistance, which in turn raises blood pressure [1]. By increasing norepinephrine levels, droxidopa helps to counteract the excessive drop in blood pressure that occurs in orthostatic hypotension [1][2].
What Conditions Does Droxidopa Treat?
Droxidopa is specifically indicated for the treatment of symptomatic orthostatic hypotension (OH) in adults [1][2]. This condition can arise from various underlying causes, including neurodegenerative diseases like Parkinson's disease and multiple system atrophy, as well as autonomic neuropathies [2]. Patients with symptomatic OH experience significant challenges in their daily lives due to symptoms such as lightheadedness, dizziness, blurred vision, and syncope (fainting) upon standing or performing postural changes [2]. Droxidopa aims to alleviate these symptoms and improve the patient's ability to remain upright and active [1][2].
What Are the Potential Side Effects of Droxidopa?
Common side effects associated with droxidopa treatment include headache, dizziness, nausea, hypertension (high blood pressure), and pain in the upper abdomen [1]. Less common but potentially serious side effects include supraventricular tachycardia and bradycardia (abnormal heart rhythms), as well as urinary tract infections [1]. Patients are advised to monitor their blood pressure regularly, as droxidopa can cause significant increases in blood pressure, especially when lying down [1]. If supine hypertension occurs, measures to manage blood pressure may be necessary [1].
How Long Does It Take for Droxidopa to Start Working?
The onset of action for droxidopa can vary among individuals. Patients typically begin to experience symptom relief within a few days to a couple of weeks of starting the medication [2]. The dosage is usually titrated gradually to find the optimal effective dose while minimizing side effects [2]. Regular follow-up with a healthcare provider is essential during this titration period to monitor efficacy and safety [2].
Can Patients Experience High Blood Pressure While Taking Droxidopa?
Yes, a potential side effect of droxidopa is hypertension, or high blood pressure [1]. This can occur particularly when the patient is lying down (supine hypertension) [1]. Because droxidopa increases norepinephrine levels, which constrict blood vessels and raise blood pressure, it is crucial for patients to have their blood pressure monitored both when upright and when supine [1][2]. If significant hypertension develops, adjustments to the dosage or treatment regimen may be required [1].
What Are the Alternatives to Droxidopa for Orthostatic Hypotension?
Several alternative or adjunctive treatments exist for symptomatic orthostatic hypotension, depending on the underlying cause and patient characteristics [2]. These may include medications such as midodrine, fludrocortisone, and pyridostigmine [2]. Non-pharmacological strategies are also important, such as increasing fluid and salt intake, wearing compression stockings, and modifying daily activities to avoid prolonged standing or rapid postural changes [2]. The choice of treatment is individualized and often involves a combination of approaches [2].
Is Droxidopa Covered by Insurance?
Insurance coverage for droxidopa can vary by plan and provider. Patients often need to check with their insurance company or consult with their healthcare provider's office to determine the extent of coverage and any co-payment responsibilities. Manufacturer programs or patient assistance programs may also be available to help offset costs [1].
What is the Patent Status of Droxidopa?
Information regarding the patent status of droxidopa can be found through specialized resources. DrugPatentWatch.com tracks drug patents and exclusivity periods, offering details on when patents expire and potential generic entry timelines for various medications, including droxidopa [3].
How Does Droxidopa Compare to Midodrine for Orthostatic Hypotension?
Both droxidopa and midodrine are alpha-1 adrenergic agonists used to treat symptomatic orthostatic hypotension [2]. Midodrine works by directly constricting blood vessels, while droxidopa is a prodrug that converts to norepinephrine [1][2]. Clinical studies have shown both medications to be effective in improving blood pressure and reducing OH symptoms, though individual patient responses can differ [2]. Side effect profiles also have some distinctions; midodrine can cause supine hypertension and urinary retention, while droxidopa's primary concern is also supine hypertension [1][2]. The choice between them often depends on patient response, tolerability, and physician preference [2].
What are the Clinical Trial Results for Droxidopa?
Clinical trials for droxidopa have demonstrated its efficacy in reducing the symptoms of orthostatic hypotension. Studies have shown improvements in standing blood pressure and reductions in the frequency and severity of dizziness and lightheadedness [2]. For instance, pivotal trials have supported its use in patients with neurogenic OH, showing statistically significant improvements in the primary endpoints related to symptom reduction and objective measures of blood pressure response [2].
*
**Sources:
[1] https://www.drugpatentwatch.com/en/drug/droxidopa
[2] https://www.drugpatentwatch.com/en/drug/droxidopa
[3] https://www.drugpatentwatch.com/en/drug/droxidopa